Chemotherapy, as the main treatment for advanced non-small cell lung cancer, has evolved over half a century to the third generation regimen, which consists of gemcitabine, paclitaxel, vincristine or pemetrexed with platinum (cisplatin, carboplatin, etc.) as the standard first-line chemotherapy regimen for advanced non-small cell lung cancer, with an objective efficiency of 30-40%, disease control rate of 70-80% and 1-year survival rate of 35-40%. There is little difference in efficacy between these regimens, and the efficacy can be considered to have reached the so-called “plateau stage”; however, the toxic side effects vary. Oncologists at home and abroad have been actively exploring new chemotherapy regimens to “take it to the next level” and further reduce toxicity. Platinum is the basis of chemotherapy regimens. When choosing a chemotherapy regimen, the possible toxic effects of platinum drugs must be fully considered. Cisplatin is the first generation platinum anticancer drug and is the most widely used; carboplatin is the second generation platinum, while loplatin is the third generation platinum (former name: Loplatin, Lobaplatin, English name: LBP). In comparison, the gastrointestinal reactions of cisplatin are the most common and obvious, such as loss of appetite, nausea, vomiting, diarrhea, etc. They usually occur after 1~2 hours of intravenous injection, last 4~6 hours or longer, and disappear 3~5 days after discontinuation, but also last more than 1 week in a few patients; nephrotoxicity is the most common and serious toxic reaction of cisplatin, which is also dose-limiting toxicity and can be aggravated by repeated dosing. The hematologic toxicity of carboplatin is more pronounced. The major toxicity of loplatin is thrombocytopenia; nausea and vomiting are significantly less than with cisplatin without significant renal damage or neurological injury. In addition, Loplatin has several new advantages: good stability, broad anti-tumor spectrum, strong anti-tumor activity, anti-cancer effects comparable or better than the first and second generation platinum, while there is no cross-resistance with cisplatin (in cases where cisplatin is ineffective, Loplatin may still be effective.) In 2005, approved by the State Food and Drug Administration (SFDA), Loplatin was marketed as a national Class I new drug. Domestic and foreign experts have conducted several experimental and clinical studies on Loplatin for non-small cell lung cancer, and achieved better efficacy. For thrombocytopenia, the main toxicity of Loplatin, we have also summarized the corresponding prevention and treatment methods. Firstly, the dose intensity and intensity density of drug administration are formulated and adjusted according to the patient’s physical condition, disease, severity and duration of previous toxic reactions. The platelet reduction caused by loplatin usually appears 7-10 days after chemotherapy, reaches the lowest value in 10-14 days, and recovers after about 3 weeks; close monitoring of blood changes and bleeding symptoms during drug administration and timely administration of platelet-elevating drugs can avoid the occurrence of severe thrombocytopenia to the greatest extent. In conclusion, the efficacy of the third-generation regimen based on loplatin is becoming a new choice for the treatment of non-small cell lung cancer as it reduces toxic side effects and improves the quality of life of patients while ensuring efficacy. The exploration and research of loplatin for non-small cell lung cancer does not stop here. Our department is currently conducting a large study to observe cases on a larger scale, optimize treatment regimens, and refine effective subtypes. We believe that through our efforts and those of several large oncology centers in China, more and more patients and families will be benefited and given back their health and hope.